Immunocore announces Fidelity’s Participation in $320M Financing

Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the participation of Fidelity Management & Research Company (“Fidelity”) in its US $320 million (£205 million) private financing round, previously announced on 16 July 2015.